.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,965,163

« Back to Dashboard

Details for Patent: 5,965,163

Title: Substained release compositions and a method of preparing pharmaceutical compositions
Abstract:A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.
Inventor(s): Miller; Ronald Brown (Basel, CH), Leslie; Stewart Thomas (Cambridge, GB), Malkowska; Sandra Therese Antoinette (Cambridge, GB), Prater; Derek Allan (Cambridge, GB), Knott; Trevor John (Essex, GB), Heafield; Joanne (Cambridge, GB), Challis; Deborah (Kent, GB)
Assignee: Euro-Celtique, S.A. (Luxembourg, LU)
Filing Date:Sep 30, 1997
Application Number:08/944,106
Claims:1. A solid dosage form comprising a plurality of particles, the plurality of particles including a pharmaceutically active substance in a matrix, the matrix including a fusible material having a melting point of from 35.degree. C. to 150.degree. C. the fusible material including a mixture of a hydrophobic fusible carrier and a hydrophilic fusible carrier, wherein said particles are formed by the process of:

(a) controlling a granulation process to produce irregular shaped agglomerates;

(b) comminuting the agglomerates to provide controlled release particles in a size range of about 0.5 mm to about 2 mm;

(c) mechanically working the agglomerates.

2. The solid dosage form according to claim 1, wherein said process further comprises adding a release control component to said mixture of a hydrophobic fusible carrier and hydrophilic fusible carrier wherein said release control component is selected from the group consisting of a water soluble fusible material, a particulate organic material, a particulate inorganic material, a particulate organic material, a particulate inorganic material, and mixtures thereof.

3. The solid dosage form according to claim 1, wherein the pharmaceutically active substance is an opioid.

4. The solid dosage form according to claim 3, wherein said opioid is morphine, tramadol, hydromorphone, oxycodone, diamorphine or a pharmaceutically acceptable salt thereof.

5. The solid dosage form according to claim 1, wherein said hydrophobic fusible carrier is a material selected from the group consisting of hydrogenated vegetable oil and hydrogenated castor oil.

6. The solid dosage form according to claim 2, wherein said release control component of water-soluble fusible material is a polyethylene glycol.

7. The solid dosage form according to claim 2, wherein said release control component is selected from the group consisting of polyethylene glycol, dicalcium phosphate, calcium sulfate, talc, colloidal anhydrous silica, lactose, poloxamers, microcrystalline cellulose, starch, hydroxypropyl-cellulose and hydroxypropylmethylcellulose.

8. The solid dosage form according to claim 1, wherein steps a and c are performed using a high speed mixer and wherein additional energy is provided to the agglomerates being mixed by the high speed mixer by microwave energy.

9. The solid dosage form according to claim 1, wherein the dosage form contains morphine sufficient to provide a plasma concentration of morphine effective to provide an analgesic effect for 24 hours after administration of said dosage form.

10. The solid dosage form according to claim 9, wherein the active substance is morphine sulfate which upon administration provides peak plasma levels of from 3.2 to 29.2 ng/ml of morphine at median times between about 2 and about 6 hours following administration.

11. The solid dosage form according to claim 1, wherein the active substance is morphine sulfate which upon administration provides a mean maximum plasma concentration (C.sub.max) of 9.2 ng/ml at a median time to reach maximum plasma concentration (T.sub.max) of said active in about 2.5 hours, and a C.sub.max of 11.9 ng/ml at median T.sub.max of about 4 hours.

12. The solid dosage form according to claim 1, wherein the hydrophobic carrier is at least 25% by weight of the total amount of ingredients added.

13. The solid dosage form according to claim 1, wherein the granulation process further comprises addition of microwave energy to the granulation mix.

14. The solid dosage form according to claim 10, wherein the hydrophobic carrier is at least 40% by weight of the total amount of ingredients added.

15. The solid dosage form according to claim 1, wherein said particles are compressed into a tablet.

16. The solid dosage form according to claim 1, wherein said particles are disposed in a capsule.

17. The solid dosage form according to claim 1, wherein step (c) is repeated from one to five times.

18. The solid dosage form of claim 1, wherein steps (b) and (c) are repeated from one to five times.

19. The solid dosage form of claim 1, wherein step (c) further includes mechanically working the agglomerates with a hydrophilic fusible carrier, a hydrophobic fusible carrier, a diluent, or mixtures thereof.

20. A solid dosage form comprising a plurality of particles the plurality of particles including a pharmaceutically active substance in a matrix the matrix including a hydrophobic fusible carrier having a melting point of from 35.degree. C. to 150.degree. C. selected from the group consisting of a hydrogenated vegetable oil, castor oil, and mixtures thereof wherein said particles are formed by the process of:

(a) controlling a granulation process to produce irregular shaped agglomerates;

(b) comminuting the agglomerates to provide controlled release particles in a size range of about 0.5 to about 2 mm;

(c) mechanically working the agglomerates.

21. The solid dosage form according to claim 20, wherein said process further comprises adding particulate fusible material in the amount of between 5% and 75% w/w to said irregular-shaped agglomerates and mechanically working said irregular shaped agglomerates and said particulate fusible material.

22. The solid dosage form according to claim 20, further comprising a hydrophilic carrier.

23. The solid dosage form of claim 20, wherein step (c) is repeated from one to five times.

24. The solid dosage form of claim 20, wherein steps (b) and (c) are repeated from one to five times.

25. The solid dosage form of claim 20, wherein step (c) further includes mechanically working the agglomerates with a hydrophilic fusible carrier, a hydrophobic fusible carrier, a diluent, or mixtures thereof.

26. A solid dosage form comprising a plurality of particles, the plurality of particles including a pharmaceutically active substance selected from the group consisting of morphine, tramadol, hydromorphone, oxycodone, diamorphine, and pharmaceutically acceptable salts thereof, in a matrix, the matrix including a fusible material having a melting point of from 35.degree. C. to 150.degree. C., the fusible material including a mixture of a hydrophobic fusible carrier and a hydrophilic fusible carrier, wherein said particles are formed by the process of:

(a) controlling a granulation process to produce irregular shaped agglomerates;

(b) comminuting the agglomerates to provide controlled release particles in a size range of about 0.5 mm to about 2 mm;

(c) mechanically working the agglomerates.

27. The solid dosage form according to claim 26, wherein step (c) is repeated from one to five times.

28. The solid dosage form of claim 26, wherein steps (b) and (c) are repeated from one to five times.

29. The solid dosage form of claim 26, wherein step (c) further includes mechanically working the agglomerates with a hydrophilic fusible carrier, a hydrophobic fusible carrier, a diluent, or mixtures thereof.

30. A solid dosage form comprising a plurality of particles, the plurality of particles including a pharmaceutically active substance selected from the group consisting of morphine, tramadol, hydromorphone, oxycodone, diamorphine, and pharmaceutically acceptable salts thereof, in a matrix, the matrix including a hydrophobic fusible carrier having a melting point of from 35.degree. C. to 150.degree. C., the hydrophobic fusible carrier selected from the group consisting of a hydrogenated vegetable oil, castor oil, and mixtures thereof, wherein said particles are formed by the process of:

(a) controlling a granulation process to produce irregular shaped agglomerates;

(b) comminuting the agglomerates to provide controlled release particles in a size range of about 0.5 to about 2 mm;

(c) mechanically working the agglomerates.

31. The solid dosage form according to claim 30, wherein step (c) is repeated from one to five times.

32. The solid dosage form of claim 30, wherein steps (b) and (c) are repeated from one to five times.

33. The solid dosage form of claim 30, wherein step (c) further includes mechanically working the agglomerates with a hydrophilic fusible carrier, a hydrophobic fusible carrier, a diluent, or mixtures thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc